In vivo and in vitro anti-inflammatory and anti-nociceptive activities of lovastatin in rodents

Brazilian Journal of Medical and Biological Research

Volumn 44, Issue 2, 2011, Pages 173-181

  Goncalves D O ^a   Calou, I B F ^a   Siqueira, R P ^a   Lopes, A A ^a   Leal, L K A ^b   Brito, G A C ^c   Tome A R ^d   Viana, G S B ^a,e  

^a Faculdade de Medicina   (Brazil)

^b Faculdade de Farmárcia   (Brazil)

^c Federal University of Ceará   (Brazil)

^d STATE UNIVERSITY OF CEARÁ   (Brazil)

^e Juazeiro do Norte CE   (Brazil)

Author keywords

Anti nociception; Cytokines; Inflammation; Myeloperoxidase; Statin

Indexed keywords

CARRAGEENAN; CYTOKINE; EOSIN; HEMATOXYLIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MEVINOLIN; MYELOPEROXIDASE; NALOXONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LEUKOCYTE MIGRATION; MALE; NEUTROPHIL; NONHUMAN; PAW EDEMA; PERITONITIS; RAT; STAINING;

MUS; RATTUS; RATTUS NORVEGICUS; RODENTIA;

EID: 79951472342     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2011007500001     Document Type: Article

References (40)

1. Almuti K, Rimawi R, Spevack D, Ostfeld RJ. Effects of statins beyond lipid lowering: potential for clinical benefits. Int J Cardiol 2006; 109: 7-15.
2. McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001; 87: 28B-32B.
3. Campo VL, Carvalho I. Estatinas hipolipêmicas e novas tendências terapêuticas. Quim Nova 2007; 30: 425-430.
4. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118.
5. Kleemann R, Princen HM, Emeis JJ, Jukema JW, Fontijn RD, Horrevoets AJ, et al. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation 2003; 108: 1368-1374.
6. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352: 29-38.
7. Puddu P, Puddu GM, Muscari A. HMG-CoA reductase inhibitors: Is the endothelium the main target? Cardiology 2001; 95: 9-13.
8. Degraeve F, Bolla M, Blaie S, Creminon C, Quere I, Boquet P, et al. Modulation of COX-2 expression by statins in human aortic smooth muscle cells. Involvement of geranylgeranylated proteins. J Biol Chem 2001; 276: 46849-46855.
9. Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H, Yasuhara M, et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001; 154: 87-96.
10. Kirsch C, Eckert GP, Koudinov AR, Muller WE. Brain cholesterol, statins and Alzheimer's disease. Pharmacopsychiatry 2003; 36 (Suppl 2): S113-S119.
11. Diomede L, Albani D, Sottocorno M, Donati MB, Bianchi M, Fruscella P, et al. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 2001; 21: 1327-1332.
12. Waehre T, Damas JK, Gullestad L, Holm AM, Pedersen TR, Arnesen KE, et al. Hydroxymethylglutaryl coenzyme A reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J Am Coll Cardiol 2003; 41: 1460-1467.
13. Rashtchizadeh N, Argani H, Ghorbanihaghjo A, Nezami N, Safa J, Montazer-Saheb S. C-reactive protein level following treatment and withdrawal of lovastatin in diabetic nephropathy. Iran J Kidney Dis 2009; 3: 93-98.
14. Nezic L, Skrbic R, Dobric S, Stojiljkovic MP, Jacevic V, Satara SS, et al. Simvastatin and indomethacin have similar anti-inflammatory activity in a rat model of acute local inflammation. Basic Clin Pharmacol Toxicol 2009; 104: 185-191.
15. Murakami M, Goto T, Saito Y, Goto S, Kochi M, Ushio Y. The inhibitory effect of simvastatin on growth in malignant gliomas - with special reference to its local application with fibrin glue spray in vivo. Int J Oncol 2001; 19: 525-531.
16. Cheng SM, Lai JH, Yang SP, Tsao TP, Ho LJ, Liou JT, et al. Modulation of human T cells signaling transduction by lovastatin. Int J Cardiol 2010; 140: 24-33.
17. Vinegar R, Truax JF, Selph JL. Some quantitative temporal characteristics of carrageenin-induced pleurisy in the rat. Proc Soc Exp Biol Med 1973; 143: 711-714.
18. Dubuisson D, Dennis SG. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 1977; 4: 161-174.
19. Lucisano YM, Mantovani B. Lysosomal enzyme release from polymorphonuclear leukocytes induced by immune complexes of IgM and of IgG. J Immunol 1984; 132: 2015-2020.
20. Eto M, Kozai T, Cosentino F, Joch H, Luscher TF. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 2002; 105: 1756-1759.
21. Nezic L, Skrbic R, Dobric S, Stojiljkovic MP, Satara SS, Milovanovic ZA, et al. Effect of simvastatin on proinflammatory cytokines production during lipopolysaccharide-induced inflammation in rats. Gen Physiol Biophys 2009; 28: 119-126.
22. Massaro M, Zampolli A, Scoditti E, Carluccio MA, Storelli C, Distante A, et al. Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: antiangiogenic actions possibly contributing to plaque stability. Cardiovasc Res 2010; 86: 311-320.
23. Dantas AC, Batista-Júnior FF, Macedo LF, Mendes MN, Azevedo IM, Medeiros AC. Protective effect of simvastatin in the cyclophosphamide-induced hemorrhagic cystitis in rats. Acta Cir Bras 2010; 25: 43-46.
24. Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, et al. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin Ther 2008; 30: 2298-2313.
25. Nahrendorf M, Sosnovik D, Chen JW, Panizzi P, Figueiredo JL, Aikawa E, et al. Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury. Circulation 2008; 117: 1153-1160.
26. Sautebin L, Ialenti A, Ianaro A, Di Rosa M. Endogenous nitric oxide increases prostaglandin biosynthesis in carrageenin rat paw oedema. Eur J Pharmacol 1995; 286: 219-222.
27. Salvemini D, Wang ZQ, Wyatt PS, Bourdon DM, Marino MH, Manning PT, et al. Nitric oxide: a key mediator in the early and late phase of carrageenan-induced rat paw inflammation. Br J Pharmacol 1996; 118: 829-838.
28. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001; 21: 115-121.
29. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002; 2: 725-734.
30. Wu KK. Control of cyclooxygenase-2 transcriptional activation by pro-inflammatory mediators. Prostaglandins Leukot Essent Fatty Acids 2005; 72: 89-93.
31. Rydgren T, Vaarala O, Sandler S. Simvastatin protects against multiple low-dose streptozotocin-induced type 1 diabetes in CD-1 mice and recurrence of disease in nonobese diabetic mice. J Pharmacol Exp Ther 2007; 323: 180-185.
32. Mantovani A, Bussolino F, Introna M. Cytokine regulation of endothelial cell function: from molecular level to the bedside. Immunol Today 1997; 18: 231-240.
33. Borthakur A, Bhattacharyya S, Dudeja PK, Tobacman JK. Carrageenan induces interleukin-8 production through distinct Bcl10 pathway in normal human colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol 2007; 292: G829-G838.
34. Stoll LL, McCormick ML, Denning GM, Weintraub NL. Antioxidant effects of statins. Drugs Today 2004; 40: 975-990.
35. Santodomingo-Garzon T, Cunha TM, Verri WA Jr, Valerio DA, Parada CA, Poole S, et al. Atorvastatin inhibits inflammatory hypernociception. Br J Pharmacol 2006; 149: 14-22.
36. Wahane VD, Kumar VL. Atorvastatin ameliorates inflammatory hyperalgesia in rat model of monoarticular arthritis. Pharmacol Res 2010; 61: 329-333.
37. Mandosi E, Fallarino M, Gatti A, Carnovale A, Rossetti M, Lococo E, et al. Atorvastatin downregulates monocyte CD36 expression, nuclear NFkappaB and TNFalpha levels in type 2 diabetes. J Atheroscler Thromb 2010; 17: 539-545.
38. Trocha M, Merwid-Lad A, Szuba A, Chlebda E, Piesniewska M, Sozanski T, et al. Effect of simvastatin on nitric oxide synthases (eNOS, iNOS) and arginine and its derivatives (ADMA, SDMA) in ischemia/reperfusion injury in rat liver. Pharmacol Rep 2010; 62: 343-351.
39. Bonnefous C, Payne JE, Roppe J, Zhuang H, Chen X, Symons KT, et al. Discovery of inducible nitric oxide synthase (iNOS) inhibitor development candidate KD7332, part 1: Identification of a novel, potent, and selective series of quinolinone iNOS dimerization inhibitors that are orally active in rodent pain models. J Med Chem 2009; 52: 3047-3062.
40. Walker JS. Anti-inflammatory effects of opioids. Adv Exp Med Biol 2003; 521: 148-160.